COEP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Coeptis Therapeutics Holdings Inc (COEP) is not a strong buy for a beginner, long-term investor at this time. While the stock has shown recent price momentum, the overbought RSI, lack of significant trading trends, weak financial performance, and absence of positive news or catalysts suggest caution. The investor's long-term strategy and preference for stability do not align with the current speculative nature of this stock.
The stock's MACD is positive and expanding, indicating bullish momentum. However, the RSI of 80.954 indicates the stock is overbought, suggesting a potential pullback. The stock is trading near its R2 resistance level of 16.913, which may act as a ceiling for further price increases. Moving averages are converging, showing no clear trend direction.
The stock has shown strong recent price momentum with a 7.35% regular market gain and additional post-market gains of 2.14%.
No recent news, no significant hedge fund or insider trading trends, and no recent congress trading data. Financial performance is weak, with declining net income (-19% YoY) and EPS (-69.47% YoY).
In Q4 2025, revenue remained flat YoY at $862,049. Net income dropped significantly to -$1,577,869 (-19% YoY), and EPS fell sharply to -0.29 (-69.47% YoY). Gross margin remained stable at 65.76%. Overall, the financials indicate weak growth and profitability.
No analyst ratings or price target changes available.
